Heidelberg Innovation

Dr Heinrich Hornef, longterm chairman of various boards of Heidelberg Innovation, has stepped down. His successor in all three committees is Dr Thorlef Spickschen, elected and effective as of December 2003. Spickschen served as the CEO of Eli Lilly before he joined the managing team of Boehringer Mannheim in 1985. In 1994 he joined Knoll AG, the pharmaceutical arm of BASF, where he served as CEO until 2001. Spickschen was also a member of the board of german pharmaceutical companies and of EFPIA (European Federation of Pharmaceutical Industries and Associations). Dr Hornef, who hands over his chair position to Dr Spickschen for reasons of age, will continue to support the company with his advice and experience in the future. In his capacity of vice chairman of the boards he will continue to take part in the development of Heidelberg Innovation, which focuses on biotechnology and life science.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH